A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 30, 2017

Primary Completion Date

March 20, 2024

Study Completion Date

March 20, 2024

Conditions
Gastrointestinal NeoplasmsAdenocarcinoma
Interventions
BIOLOGICAL

IMU-131

IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant

DRUG

Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.

Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).

Trial Locations (22)

2025

ARENSIA Exploratory Medicine IMSP Institutul Oncologic, Chisinau

8112

ARENSIA Exploratory Medicine LLC, Kapitanivka

10400

National Cancer Institute of Thailand, Bangkok

11000

Institute for Oncology and Radiology of Serbia - PPDS, Belgrade

Military Medical Academy, Belgrade

11070

Clinical Hospital Center Bezanijska Kosa, Belgrade

11217

Taipei Veterans General Hospital, Taipei

21204

Oncology Institute of Vojvodina, Kamenitz

50200

Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai

70403

National Cheng-Kung University Hospital, Tainan City

90110

Division of Medical Oncology, Department of Medicine, Prince of Songkla University, Songklanagarind Hospital, Hat Yai

411004

Deenanath Mangeshkar Hospital and Research Centre, Pune

422004

Curie Manavata Cancer Centre, Nashik

440026

HCG NCHRI Cancer Centre, Nagpur

500004

MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad

520002

City Cancer Center, Vijayawada

560002

Victoria Hospital, Bangalore

560068

Shetty's Hospital, Bengaluru

700160

Tata Medical Centre, Kolkata

781023

North East Cancer Hospital and Research Institute, Guwahati

800014

Regional Cancer Centre Indira Gandhi Institute of Medical Sciences, Patna

0112

ARENSIA Exploratory Medicine LLC, Tbilisi

All Listed Sponsors
lead

Imugene Limited

INDUSTRY

NCT02795988 - A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter